Cisatracurium is a skeletal muscle relaxant used to facilitate tracheal intubation, muscle relaxation in surgery, or mechanical ventilation. Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.
- Mechanism
- Curator reviewed · 2 references
Like other non-depolarising neuromuscular blocking agents, cisatracurium binds competitively to cholinergic receptors in motor end-plate neurons, blocking acetylcholine from accessing the receptors. Therefore, in the presence of cisatracurium, an end-plate potential cannot be developed. Ion channels remain closed, the cell does not depolarize, and an action potential is not transmitted.
- Primary indication
- Cisatracurium is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age.Curator reviewed · 3 structured indications
- Formula / weight
- C53H72N2O12 · 929.16 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1995
- Also known as
- Cis-Atracurium · Cisatracurium cation
- Brand names
Resolves to
YXSLJKQTIDHPOT-LJCJQEJUSA-NSMILESCOC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2What you can answer from here — as of September 23, 2026
Which drugs share a target with Cisatracurium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account